A recent advance in bioelectronic medicine may be able to stop internal or external bleeding by stimulating certain nerves in the brain using a “neural tourniquet.” Researchers from the Feinstein Institute for Medical Research (FIMR) believe the treatment could be used in battlefield medicine, emergency care, surgery, or post-partum treatments to treat or prevent hemorrhaging.
A cloture vote by the U.S. Senate on Tuesday has ended debate in the Senate over the 21st Century Cures Act and paved the way for a vote on passage of the bill, which could happen as soon as today. Under cloture, a procedure intended to break filibusters, the Senate may limit consideration of a pending matter to 30 additional hours of debate.
Teleflex has entered into a definitive agreement to acquire Vascular Solutions for $1B, a move that will launch Teleflex into the coronary and peripheral vascular markets.
Boston Scientific continues to diversify its foothold in the cardiovascular space, signing a definitive agreement to acquire select technologies and manufacturing capabilities from Neovasc, a Canadian biological tissue business specializing in elements used to build transcatheter heart valves.
President-elect Donald Trump has nominated U.S. Rep. Tom Price (R-GA.) as secretary of the Department of Health and Human Services (HHS), and tabbed Seema Verma, a healthcare consultant, to head the Centers for Medicare and Medicaid Services (CMS).
Medtronic has inked an Integrated Health Solutions agreement with University Hospitals Cleveland Medical Center (UH), the first agreement of its kind signed by Medtronic in the U.S. Together, the organizations will implement Medtronic’s operational models to streamline workflow and efficiency in select catherization (cath) and electrophysiology (EP) laboratories.
LG Electronics signaled its entry into the medical imaging market with the announcement of three new devices: a clinical review monitor, a surgical monitor, and a digitized x-ray detector for radiography.
National Institute of Standards and Technology (NIST) researchers have uncovered a possible solution for incorporating non-toxic, but brittle, gold circuitry into sensing platforms that are flexible enough to be worn inside or outside the body for an extended period of time.
FDA is considering a new drug application (NDA) from biopharmaceutical company Intarcia Therapeutics for ITCA 650, an investigational therapy for type II diabetes that uses an implanted mini-pump to continuously release the drug. Intarcia CEO Kurt Graves commented that the disruptive technology, if approved, would be the first and only injection free glucagon-like peptide-1 (GLP-1) receptor agonist therapy.
Sensor technology attached to cardiac implants can successfully predict heart failure events 70 percent of the time, according to an international team of scientists that included representatives from Boston Scientific and Penn State Medical Center.